Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 977-986

  Harrop, Richard ^a   Drury, Noel ^a   Shingler, William ^a   Chikoti, Priscilla ^a   Redchenko, Irina ^a   Carroll, Miles W ^a,d   Kingsman, Susan M ^a   Naylor, Stuart ^a   Griffiths, Richard ^b   Steven, Neil ^c   Hawkins, Robert E ^b  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d R2D Ltd   (United Kingdom)

Author keywords

Chemo immuno therapy; Colorectal cancer; Immune response; Tumor antigen; Vaccine

Indexed keywords

5T4 ANTIBODY; CANCER ANTIBODY; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; HLA A2 ANTIGEN; IRINOTECAN; TROVAX; VIRUS VECTOR;

ADULT; AGED; ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HICKMAN LINE INFECTION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LETHARGY; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VACCINIA VIRUS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; LEUCOVORIN; MALE; MIDDLE AGED;

EID: 42649138944     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0428-7     Document Type: Article

References (22)

1. Braybrooke JP, Slade A, Deplanque G et al (2005) Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 11:1512
2. Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632
3. Ghiringhelli F, Larmonier N, Schmitt E et al (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336
4. Griffiths RW, Gilham DE, Dangoor A et al (2005) Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 93:670
5. Harrop R, John J, Carroll MW (2006) Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev 58:931
6. + T cell dependent and antibody mediated. Cancer Immunol Immunother 55:1081
7. Harrop R, Connolly N, Redchenko I et al (2006) Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12:3416
8. Harrop R, Drury N, Shingler W et al (2007) Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13:4487
9. Hermans IF, Chong TW, Palmowski MJ et al (2003) Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408
10. Hole N, Stern PL (1988) A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 57:239
11. Lake RA, Robinson BWS (2005) Immunotherapy and chemotherapy-practical partnership. Nature Rev Cancer 5:397
12. Leonard P, Seymour MT, James R et al (2002) Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216
13. Lutsiak ME, Semnani RT, De Pascalis R et al (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862
14. Marshall JL, Hoyer RJ, Toomey MA et al (2000) Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964
15. Rochlitz C, Figlin R, Squiban P et al (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690
16. Southall PJ, Boxer GM, Bagshawe KD et al (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61:89
17. Starzynska T, Rahi V, Stern PL (1992) The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 66:867
18. Starzynska T, Marsh PJ, Schofield PF et al (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 69:899
19. Sutter G, Moss B (1992) Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89:10847
20. Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229
21. Weihrauch MR, Ansen S, Jurkiewicz E et al (2005) Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Can Res 11:5993
22. Wrigley E, McGowan AT, Rennison J et al (1995) 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 5:269